Noninvasive prenatal testing (NIPT) using cell-free DNA (cfDNA) from maternal serum has been clinically available since 2011. This technology has revolutionized our ability to screen for the common aneuploidies trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. More recently, clinical laboratories have offered screening for other chromosome abnormalities including sex chromosome abnormalities and copy number variants (CNV) without little published data on the sensitivity, specificity, and positive predictive value. In this debate, the pros and cons of performing prenatal screening via cfDNA for all chromosome abnormalities is discussed. At the time of the debate in 2017, the general consensus was that the literature does not yet support using this technology to screen for all chromosome abnormalities and that education is key for both providers and the patients so that the decision-making process is as informed as possible.
| INTRODUCTION (LOUANNE HUDGINS)
Thus, the statement for debate is that cfDNA prenatal screening should be used to identify all chromosome abnormalities.
| FOR (MARY NORTON)
Cell-free DNA was introduced in 2011 as a clinically available test for Down syndrome. Subsequently, testing for trisomies 13 and 18, the sex chromosomes were added to most laboratories' panels. Since that time, the technology has advanced such that noninvasive prenatal testing is now commercially available for sex chromosomal aneuploidies, microdeletions and duplications, large CNVs across the genome, and, most recently, some single gene disorders. However, these advances come at a cost-with increasing numbers of disorders added to the panels, the false-positive rates increase and the positive predictive value (PPV) of the test taken as a whole decreases. The benefit of testing for these broad panels of conditions is the topic of current, often heated debate. As additional conditions will undoubtedly continue to be added to these panels, there is no doubt these important issues will continue to be discussed.
There are several arguments in favor of expanding cfDNA panels to include all possible chromosome conditions. First, there is no rationale for only testing for 3 common aneuploidies. Arguably, in an era when broad genomic screening is possible, one would not choose to specifically screen for only Down syndrome and trisomies 13 and 18-Down syndrome is common but far less severe than many other conditions, and rates of termination are decreasing over time. 3 Trisomies 13 and 18 are most often lethal in utero or soon after birth; there is therefore limited benefit to prenatal detection of these conditions. diagnostic test (amniocentesis and karyotype). Prenatal diagnosis did not set out with a goal to identify cases of Down syndrome before birth because that was felt to be the most important condition; rather, decisions were made as to whom should be offered prenatal diagnosis for Down syndrome once such testing was developed. 4 The field continues to be driven by the technology more than by a predetermined need to detect specific conditions in the prenatal period. In 2017, it makes little sense to spend so much effort in screening for this 1 condition that is far less severe than many other testable disorders.
Prenatal screening should focus on genomic testing rather than individual conditions and disorders; detection of other conditions undoubtedly provides far greater clinical utility.
Microdeletions, which are now available on many cfDNA panels, are more common than Down syndrome for women under 30 years old. 5 Overall, CNVs are estimated to contribute 15% of disease burden in children, 6 and screening of these would therefore identify many more pregnancies at risk than screening for just the 3 common aneu- Next, although the PPV of cfDNA screening is lower for rare disorders, the test is still better than many accepted screening tests; the PPV for mammography and PAP smear screening, for example, are lower than for cfDNA screening for microdeletions. And certainly, the PPV even for rare microdeletions appears to be higher than for first trimester combined screening, which is a highly accepted test. [9] [10] [11] Importantly, this technology is available, and patients are aware of this as an option in prenatal testing. Denying women available tests is difficult to justify ethically.
If the argument against broadening the cfDNA screening panels is that the PPV is low, or that women are misled into believing that this test is an equivalent alternative to diagnostic testing, it would appear that the concern is largely with the implementation process. The primary argument against cfDNA screening appears to be a lack of understanding of the test and how well women and their providers understand the limitations as compared with diagnostic testing and the far more comprehensive testing provided by chromosomal microarray (CMA). In this case, the solution is better education rather than withholding the test.
As new diagnostic and therapeutic techniques become available, there are often those who hesitate to encourage use of such methods.
In many areas of medicine, there have been those who argued against progress, be it heart transplantation, fetal surgery, stem cell transplantation, or other treatments that have become relatively routine. It is by "pushing the envelope" that the field evolves. Truthfully, there is no going back, and our focus should be on improving education rather than withholding technology.
| AGAINST (LYN CHITTY)
The principles of screening include the fact that the condition(s) screened for should be an important health problem. There should be a test for the condition(s) that should have a high sensitivity, specificity, and PPV, and the test should be acceptable to the population. 12 Here,
What's already known about this topic?
• Analysis of cfDNA obtained from maternal plasma, also known as noninvasive prenatal testing (NIPT) and noninvasive prenatal screening (NIPS), is currently a widely used screening test for the common aneuploidies: trisomy 21, trisomy 18, and trisomy 13. It is also used as a screening test for fetal sex and for sex chromosome aneuiploidy.
• The sensitivity, specificity, and PPV of cfDNA for these conditions are well described in the peer-reviewed medical literature, but there is little evidence on performance when screening for other chromosomal anomalies.
What does this study add?
• Screening for common CNVs allows for early detection and treatment as well as redirection of care and, while the PPV of cfDNA screening for CNVs is low, it is still better than that for many accepted screening tests such as mammography and Pap smear screening.
• There is a lack of understanding of the limitations of cfDNA screening for CNVs and other chromosomal anomalies compared with diagnostic testing, and the solution is "better education" rather than withholding the testing.
• However, most nonrecurrent and/or relatively small CNVs are not identified by the current clinically available cfDNA panels, the sensitivity is poor, and PPV is low resulting in a false sense of security that no CNV is present.
• The many false positives will contribute to increased invasive testing, high levels of parental anxiety, possibly unnecessary terminations of pregnancy, and increased health-care costs
• There is a general agreement that education is key for both providers and patients so that the decision process is as informed as possible.
I argue that these criteria are not fulfilled in relation to using analysis of cfDNA in maternal plasma to screen for micodeletions and duplications and other pathogenic CNVs, sex chromosome abnormalities (SCAs), and rare autosomal trisomies in addition to trisomies 13, 18, and 21. Thus, I
will argue that it should not be used to identify all chromosome abnormalities. To do this, I will, where possible, explore what happens to the sensitivity, false-positive rate, and PPV and estimate the residual risk when using "expanded" cfDNA screening.
3.1 | Pathogenic CNVs, microdeletion, and duplication syndromes
Pathogenic CNVs occur in up to 1.7% of normal pregnancies, and 6%
of those where the fetus has a structural abnormality. 5, 13, 14 There are several recurrent recognized microdeletion syndromes (Table 1) (Table 2) .
Using the evidence currently available and considering those studies where all cases had CMA, sensitivity ranges from 61% to 97.7% overall for the group of selected microdeletion syndromes tested, but when considering those cases with CNVs <5 Mb, the sensitivity decreases to 14% to 20% ( Table 2 ). In 1 case reported recently in a pregnancy at high risk of a large imbalance, cfDNA testing failed to detect this in the fetus. 21 This family had a son with Wolf-Hirschhorn syndrome, and the father was a known carrier of a balanced 4:8 translocation.
Cell The false-positive rate, which is likely to have the most clinical significance in that it may well result in increased invasive testing, high levels of parental anxiety, and possibly unnecessary terminations of pregnancy, ranges from 0.4% to 5% with a number of studies only reporting the performance to detect 22q-(DiGeorge syndrome) ( Table 2 ). Most studies report very small numbers of abnormal cases, as might be expected given the rarity of these conditions, but it must be remembered that the false-positive rate will be cumulative. In some studies, the false-positive rate is high partly due to detection of maternal rearrangements 22 ( Table 2 ). Other contributors include confined placental mosaicism, as in a recent case of a 22q11.2 deletion that was a discordant positive cfDNA test shown to be due to CPM. 23 In addition, studies do not report their failure rate for cfDNA screening for these other chromosomal rearrangements, and we know that when screening for trisomies, failed or inconclusive results may be associated with a higher rate of adverse outcome as well as resampling (at additional cost) or invasive testing. In 1 study that looked at 26 failed or inconclusive results, 9 were suggestive of microdeletion syndromes when retested and all were false positives. 24 What about the PPV for these conditions? Again, most studies report small series, with PPVs varying from 3.8% to 4.9% in low-risk pregnancies, and to 50% to 97% in high-risk pregnancies with ultrasound anomalies (Table 2) .
Finally, what about the residual risk in pregnancies that screen negative for CNVs by using expanded cfDNA? One could argue that it is acceptable to have inadequate validation data and high falsepositive rates if cfDNA screening detects most of these pathogenic rearrangements, because while the outcome is difficult to predict for many, others carry a very poor prognosis. Using data from 2 large cohorts where microarray testing was used to diagnose pathogenic CNVs in fetuses with a normal karyotype, the residual risk for a What about the detection of SCAs? Several studies report sensitivities of between 50 and 100% for 45,X and 47,XXX, 47,XXY, and 47,XYY, but as negative cases are not karyotyped and follow-up is generally poor, the true sensitivity is not known. [26] [27] [28] [29] These and other studies report false-positive rates of 0.12 to 1.1% and PPVs of between 9 and 40% for 45,X, the most common sex chromosome anomaly, and 7 to 70% for the others. As cfDNA analysis tests all cfDNA in the maternal blood, maternal and fetal, maternal SCA is a frequent cause of discordant results. 30 Furthermore, there is an exponential loss of an X-chromosome with maternal age resulting in increasing maternal mosaicism for 45,X. 31 This means the discordancy rate is likely to increase as women choose to have pregnancies later in life. All of these factors add to the false-positive rate of cfDNA screening and the potential for increasing invasive testing rates.
Another purported benefit of expanded cfDNA testing is the detection of rare autosomal trisomies. However, these are rare; most are confined to the placenta and associated with miscarriage or, rarely, intrauterine growth retardation. The clinical utility of detecting these trisomies is unclear and again can only result in increasing need for invasive testing as the incidence is reported to be between 0.1% and 0.78%.
What do women themselves want from cfDNA testing? They want to know about SCAs but want full information about conditions before undergoing testing and consider it the duty of their health professional to provide that information. They are unfamiliar with microdeletions and expressed concern about using cfDNA to detect them in view of variable or unknown phenotypic expression. 32 Furthermore, at least 12% of women do not want to know the baby's sex and report receiving information about cfDNA testing in only 5 minutes. 33 Health professionals report spending an average of 6 minutes answering parents' questions before testing-so how are we going to be able to explain the implication of expanded cfDNA screening?
In summary, the performance of cfDNA screening will decrease from sensitivities of~99% for the major trisomies to~60% as microdeletions, sex chromosome anomalies, and rare autosomal trisomies are included. With the decrease in sensitivity, there will be an increase in false-positive rates from~0.14 to >1.5% ( Figure 1 ). As most of the data to date come from high-risk pregnancies, performance will be even worse if offered to all women! This will be accompanied by decreasing clinical relevance, less or no validation data, and increasing parental anxiety and unnecessary invasive tests.
So should expanded cfDNA testing be offered to all? If it is, for those with a normal ultrasound scan and a "positive" cfDNA test, confirmatory invasive testing will be offered, largely unnecessarily as the PPV is so low in this population. If the test is "negative," this offers little reassurance in reality as the residual risk for microdeletions is virtually unchanged. So cfDNA screening will deliver increased anxiety, additional cost, unnecessary invasive tests, and the potential for unnecessary terminations. In pregnancies with an ultrasound anomaly, a "positive" cfDNA result requires invasive confirmation, and as a "negative" one does not exclude other chromosomal rearrangements, invasive testing is still needed. In this situation, all cfDNA screening offers is the potential for delayed diagnosis, additional cost, and anxiety for parents.
The answer has to be NO. Offering expanded cfDNA screening to all stands to undermine choice and parental autonomy, introduces significant complexity into counseling, does not really change the residual risk, raises unrealistic expectations, and will result in increasing the invasive testing rate and undoing the good this technology is offering.
We should listen to what our guiding bodies are saying. ACOG is clear that routine cfDNA screening for microdeletion screening should not be performed. 34 ESHG agrees and includes sex chromosome anomalies in that view, stating that "it not only raises ethical concerns related to information and counseling challenges but also risks reversing the important reduction in invasive testing achieved with implementation of NIPT for aneuploidy." 35 
| CONCLUSIONS (LOUANNE HUDGINS)
Dr Norton takes the affirmative approach that cfDNA prenatal screening should be used to identify all chromosome abnormalities. She argues that that there is no reason to choose to perform prenatal genetic screening for only the common aneuploidies. Many cases of trisomies 13 and 18 are lost in utero or soon after birth, and she states that it makes "little sense to spend so much effort in screening" for Down syndrome that is "far less severe than many other treatable disorders". On the other hand, she makes the case that screening for common CNVs allows for early detection and treatment as well as redirection of care. Dr Norton also points out that while the PPV of cfDNA screening is low for rare disorders, it is still better than that for many accepted screening tests such as mammography and Pap smear screening. She states that the argument against broadening the cfDNA screening panels is largely one regarding the implementation process, ie, that there is a lack of understanding of the limitations of this testing compared with diagnostic testing. Thus, she believes that the solution is "better education rather than withholding the testing." Dr Chitty argues against offering cfDNA prenatal screening for all chromosome abnormalities, primarily because most nonrecurrent and/ or relatively small CNVs are not identified by the current clinically available panels. She states that sensitivity is poor and that the PPV is low, which can lead to a false sense of security that no CNV is present. On the other hand, there are also many false positives that contribute to "increased invasive testing, high levels of parental anxiety and possibly unnecessary terminations of pregnancy" as well as increased health-care costs. Dr Chitty also asks the important question: What do the patients want from cfDNA prenatal screening? She points out that many women are unfamiliar with the microdeletions that are screened for and that health professionals spend very little time describing the risks and benefits of the testing. Finally, she makes the point that no guiding body in the USA or in Europe has recommended offering cfDNA prenatal genetic screening for CNVs.
At the time of the debate at ISPD, most audience members voted against offering cfDNA for all chromosome abnormalities at this point in time, both before and after the debate. There appeared to be general agreement that education is key for both providers and the patients so that the decision process is as informed as possible. We hope that our national and international governing bodies will develop and encourage educational materials in this realm.
